{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:33:22Z","timestamp":1792154002140,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"LegoChem Biosciences, Inc"},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved oxazolidinones should have a better safety profile, while preserving efficacy. Delpazolid is a novel oxazolidinone developed by LegoChem Biosciences Inc. that has been evaluated up to phase 2a clinical trials. Since oxazolidinone toxicity can occur late in treatment, LegoChem Biosciences Inc. and the PanACEA Consortium designed DECODE to be an innovative dose-ranging study with long-term follow-up for determining the exposure\u2013response and exposure\u2013toxicity relationship of delpazolid to support dose selection for later studies. Delpazolid is administered in combination with bedaquiline, delamanid and moxifloxacin.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Seventy-five participants with drug-sensitive, pulmonary tuberculosis will receive bedaquiline, delamanid and moxifloxacin, and will be randomized to delpazolid dosages of 0 mg, 400 mg, 800 mg, 1200 mg once daily, or 800 mg twice daily, for 16 weeks. The primary efficacy endpoint will be the rate of decline of bacterial load on treatment, measured by MGIT liquid culture time to detection from weekly sputum cultures. The primary safety endpoint will be the proportion of oxazolidinone class toxicities; neuropathy, myelosuppression, or tyramine pressor response.\n<\/jats:p>\n                <jats:p>Participants who convert to negative liquid media culture by week 8 will stop treatment after the end of their 16-week course and will be observed for relapse until week 52. Participants who do not convert to negative culture will receive continuation phase treatment with rifampicin and isoniazid to complete a six-month treatment course.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>DECODE is an innovative dose-finding trial, designed to support exposure-response modelling for safe and effective dose selection. The trial design allows assessment of occurrence of late toxicities as observed with linezolid, which is necessary in clinical evaluation of novel oxazolidinones. The primary efficacy endpoint is the change in bacterial load, an endpoint conventionally used in shorter dose-finding trials. Long-term follow-up after shortened treatment is possible through a safety rule excluding slow-and non-responders from potentially poorly performing dosages.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>DECODE was registered in ClinicalTrials.gov before recruitment start on 22 October 2021 (NCT04550832).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07354-5","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T20:30:13Z","timestamp":1686083413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8797","authenticated-orcid":false,"given":"A","family":"Dierig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hoelscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Jarchow-MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EM","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Te Brake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Boeree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TD","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LM","family":"Wildner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PPJ","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LT","family":"Minja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Ntinginya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mpagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Liyoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RS","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Sebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FA","family":"Mhimbira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Mbeya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rassool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Geiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YL","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"7354_CR1","unstructured":"WHO. Global Tuberculosis Report 2021. Geneva: World Health Organization; 2021."},{"issue":"3","key":"7354_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172748","volume":"12","author":"EA Kendall","year":"2017","unstructured":"Kendall EA, Azman AS, Cobelens FG, Dowdy DW. MDR-TB treatment as prevention: the projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. PLoS One. 2017;12(3): e0172748.","journal-title":"PLoS One."},{"issue":"9","key":"7354_CR3","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.5588\/ijtld.12.0959","volume":"17","author":"M Mehra","year":"2013","unstructured":"Mehra M, Cossrow N, Kambili C, Underwood R, Makkar R, Potluri R. Assessment of tuberculosis burden in China using a dynamic disease simulation model. Int J Tuberc Lung Dis. 2013;17(9):1186\u201394.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"1","key":"7354_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2011.02.022","volume":"145","author":"KN Adams","year":"2011","unstructured":"Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell. 2011;145(1):39\u201353.","journal-title":"Cell."},{"issue":"3","key":"7354_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1056\/NEJMc1500286","volume":"373","author":"M Lee","year":"2015","unstructured":"Lee M, Cho SN, Barry CE 3rd, Song T, Kim Y, Jeong I. Linezolid for XDR-TB\u2013final study outcomes. N Engl J Med. 2015;373(3):290\u20131.","journal-title":"N Engl J Med."},{"issue":"16","key":"7354_CR6","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","volume":"367","author":"M Lee","year":"2012","unstructured":"Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508\u201318.","journal-title":"N Engl J Med."},{"issue":"4","key":"7354_CR7","first-page":"603","volume":"7","author":"X Zhang","year":"2015","unstructured":"Zhang X, Falagas ME, Vardakas KZ, Wang R, Qin R, Wang J, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015;7(4):603\u201315.","journal-title":"J Thorac Dis."},{"issue":"10","key":"7354_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893\u2013902.","journal-title":"N Engl J Med."},{"issue":"4","key":"7354_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1345\/aph.1R604","volume":"47","author":"TD Ramsey","year":"2013","unstructured":"Ramsey TD, Lau TT, Ensom MH. Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach. Ann Pharmacother. 2013;47(4):543\u201360.","journal-title":"Ann Pharmacother."},{"key":"7354_CR10","unstructured":"Africa MoHS. Management of Rifampicin - Resistant Tuberculosis. In: Health, editor. 2019."},{"key":"7354_CR11","unstructured":"WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO, editor. Geneva: WHO; 2019."},{"issue":"3","key":"7354_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","volume":"7","author":"F von Groote-Bidlingmaier","year":"2019","unstructured":"von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. The Lancet Respiratory medicine. 2019;7(3):249\u201359.","journal-title":"The Lancet Respiratory medicine."},{"key":"7354_CR13","unstructured":"FDA. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. In: U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research, editor. 2009."},{"issue":"7","key":"7354_CR14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","volume":"21","author":"KE Dooley","year":"2021","unstructured":"Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021;21(7):975\u201383.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"7354_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","volume":"96","author":"EJ Dunkley","year":"2003","unstructured":"Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635\u201342.","journal-title":"QJM."},{"issue":"9","key":"7354_CR16","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","volume":"191","author":"MJ Boeree","year":"2015","unstructured":"Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191(9):1058\u201365.","journal-title":"Am J Respir Crit Care Med."},{"issue":"12","key":"7354_CR17","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1093\/jac\/dkx317","volume":"72","author":"EM Svensson","year":"2017","unstructured":"Svensson EM, Karlsson MO. Modelling of mycobacterial load reveals bedaquiline\u2019s exposure-response relationship in patients with drug-resistant TB. J Antimicrob Chemother. 2017;72(12):3398\u2013405.","journal-title":"J Antimicrob Chemother."},{"issue":"7","key":"7354_CR18","doi-asserted-by":"publisher","first-page":"e01834","DOI":"10.1128\/AAC.01834-16","volume":"61","author":"PL Olliaro","year":"2017","unstructured":"Olliaro PL, Merle C, Mthiyane T, Bah B, Kassa F, Amukoye E, et al. Effects on the QT interval of a gatifloxacin-containing regimen versus standard treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2017;61(7):e01834-16.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07354-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07354-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07354-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T20:30:37Z","timestamp":1686083437000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07354-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7354"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07354-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"assertion":[{"value":"1 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Ethic committee of the Ludwig-Maximilians-University of Munich, Germany and by applicable ethics committees of the trial sites. These include:South African Health Products and Regulatory Authority, Arcadia, South AfricaHuman Research Ethics committee, University of the Witwatersrand (Ref 200910B)Medical Research Coordinating Committee Tanzania (Ref NIMR\/HQ\/R.8a\/Vol.IX\/3649)Mbeya Medical Research and Ethics review committee, Mbeya, Tanzania (Ref SZEC-2439\/R.A.\/V.1\/105)Institutional Review Board, Ifakara Health Institute, Dar es Salaam, Tanzania (Ref IHI\/IRB\/AMM\/ No: 11-2021)Kilimanjaro Christian Medical College Research Ethics and Review Committee (CRERC), Moshi, TanzaniaWritten informed consent will be obtained from each participant or its legal guardian. The informed consent is available from the corresponding author on request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"\u201cInformed consent forms\u201d of the study may be provided by the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"All authors except LG and YLC report receiving research funding from LegoChem Biosciences to their institutions. LG receives compensation as a consultant. YLC is an employee of LegoChem Biosciences. Further, the authors would like to report receiving delamanid (Deltyba\u00ae) free of charge, from Otsuka Novel Products GmbH.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"382"}}